Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**T28** is a PHCANN International dried medicinal cannabis flower product designation within a series of THC-strength formulations. The available public pipeline information identifies it as dried cannabis flower but does not specify the cultivar, exact cannabinoid profile, terpene composition, approved indication, or a product-specific clinical development stage. Its expected pharmacology is primarily attributable to delta-9-tetrahydrocannabinol and other naturally occurring cannabis constituents, with cannabinoid-receptor activity mediating central nervous system and peripheral effects. ([phcann.com](https://phcann.com/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on T28.